Antibody-Drug Conjugates

Oxford BioTherapeutics partners with Bristol Myers Squibb to develop T-cell engager therapies for solid tumors, marking third major pharma deal in a year.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.